PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Go online to PeerView.com/BPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the management of motor complications in Parkinson’s disease. Upon completion of this accredited CE activity, participants should be better able to: Identify the need to adjust treatment for “off” episodes in Parkinson’s disease through symptom and therapy assessment and clear communication with patients and/or caregivers, Interpret evidence regarding on-demand treatment options and their role in the management of “off” episodes in Parkinson’s disease, Apply on-demand treatment options, based on current evidence, in the personalized management of “off” episodes in Parkinson’s disease.

Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.

Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.

Go online to PeerView.com/WEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss treatment with B-cell therapies in patients with multiple sclerosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Recognize the similarities and differences between anti-CD20 monoclonal antibodies available for the treatment of relapsing forms of MS, Analyze available evidence on investigational B-cell–targeting therapies, Employ a patient-centered approach to treatment selection for patients with MS based on their disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/EME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex. Upon completion of this activity, participants should be better able to: Utilize clinical and genetic diagnostic criteria to identify patients with tuberous sclerosis complex (TSC) early in the disease course, Employ updated consensus recommendations for the surveillance of patients with TSC throughout the course of their disease, Apply updated consensus recommendations for the management of patients with specific disease manifestations associated with TSC.

Go online to PeerView.com/VWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting. Upon completion of this accredited CE activity, participants should be better able to: Identify best practices and current recommendations for diagnosing patients with migraine, including risk-stratification strategies for performing a differential diagnosis in the emergency department (ED); Apply evidence-based criteria and screening tools to accurately diagnose patients presenting to the ED with migraine; Summarize data on the efficacy, safety, and tolerability of agents currently available for the acute treatment and prevention of migraine; Employ strategies to help coordinate outpatient care and integrate current therapies into personalized management plans for acute treatment and prevention of migraine.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.

Go online to PeerView.com/ZVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the role of B cells in MS pathogenesis and the use of anti-CD20 monoclonal antibodies in the management of relapsing forms of MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies in the treatment of relapsing forms of MS, Apply best practices and clinical evidence when using B-cell–depleting therapies to optimize outcomes for patients with relapsing MS.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.